Oseltamivir phosphate (OP), one NEU1 inhibitor, markedly reversed 5-FU resistance, migration, and proliferation induced by high expression of SPNS1 both in vivo and in vitro. Our findings indicated that SPNS1 might promote the progression of ESCC by upregulating NEU1 expression and influencing chemotherapy sensitivity.

2024年4月1日 · Blocking NEU1 reverses 5-FU resistance induced by SPNS1 high expression. These results suggest that SPNS1 may regulate the drug sensitivity of ESCC through the downstream target gene NEU1. NEU1 is a lysosomal enzyme that cuts through the sialic acid residues of substrates such as glycoproteins and glycolipids [28].

2024年1月1日 · The correlation between NEU1, one of the identified DEG, and SPNS1 and the potential mechanism was validated. Results: SPNS1 was significantly higher in ESCC tissues compared to adjacent normal tissues. Patients with high SPNS1 had a significantly poorer clinical prognosis than those with low SPNS1.

2024年3月8日 · Oseltamivir phosphate (OP) 是一种 NEU1 抑制剂，研究发现，OP 可以显著逆转高 SPNS1 表达所导致的 5-FU 耐药、迁移和增殖。 这些结果为 ESCC 治疗提供了新的潜在治疗靶点。

Oseltamivir Phosphate (OP), an NEU1 inhibitor, significantly reversed 5-FU resistance, migration, and proliferation induced by high SPNS1 expression both in vivo and in vitro. These findings suggest that SPNS1 may promote ESCC progression by upregulating NEU1 expression and affecting chemotherapy sensitivity [54].

ESCC undergoes a sequence of development ranging from inflammation, hyperplasia, dysplasia and carcinoma in situ to invasive carcinoma. Exploring the underlying mechanisms for the initiation and development of ESCC is extremely important …

2023年5月19日 · Neuraminidase-1 (sialidase-1 or NEU1) is a ubiquitously expressed mammalian sialidase located in lysosomes and on the cell membrane. Because of its modulation of multiple signaling processes, it is a potential therapeutic target for cancers and immune disorders.

2022年11月28日 · NEU1 has been shown to regulate MUC1 activity, which is responsible for inducing drug resistance in human (BxPC3 and Capan-1) and mouse (KCKO, KCM) pancreatic cancer cells [106,107].

2024年10月22日，中国医学科学院肿瘤医院高树庚团队在期刊《Nature Communications》上发表了题为“Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma”的研究论文。 研究结果强调了CXCL13作为辅助治疗提高免疫治疗疗效的潜力， 确定了LRRC15 CAFs和SPP1巨噬细胞的富集是免疫治疗耐药的关键标志物。 这些发现为未来研究改善ESCC免疫治疗反应的最佳策略，提供 …

科学家们进一步探索以neu1为靶点的抑制剂。利用计算机辅助药物设计策略，他们从160万个化合物中筛选到16个能与neu1形成合理氢键的化合物（c-01到c-16），并确定化合物c-09可通过靶向neu1改善病理性心肌肥厚。